Skip to main content
Clinical Trials/NCT06541899
NCT06541899
Completed
Phase 4

Safety and Efficacy of Cryolipolysis Clinical Protocols

Indústria Brasileira Equipamentos Médicos - IBRAMED3 sites in 1 country395 target enrollmentOctober 4, 2023
ConditionsFat Loss

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Fat Loss
Sponsor
Indústria Brasileira Equipamentos Médicos - IBRAMED
Enrollment
395
Locations
3
Primary Endpoint
% reduction in fat layer assessed by ultrasound, adipometer and photography
Status
Completed
Last Updated
last year

Overview

Brief Summary

A single-arm, multicenter interventional clinical study will be conducted. The objective is to evaluate the safety and efficacy of the cryolipolysis technique. Approximately 372 participants will be included. After analyzing the items listed above, the participants in each study will be divided into 3 distinct intervention groups. The individuals included in the study will undergo anamnesis and data collection.

Detailed Description

The participants in each study will be divided into 3 distinct intervention groups (Grupo 1: aplicador 360° M - Região abdominal; Grupo 2: aplicador 360° G - Região abdominal; Grupo 3: aplicador de placas - Região dos flancos). After analyzing the inclusion and exclusion criteria of this study, the individuals included in the study will undergo anamnesis and data collection after the procedure and 6 weeks and 20 weeks after: photographic capture, bioimpedance, perimetry, adipometry and ultrasound imaging of the treated area, in addition to a pain and patient satisfaction questionnaire.

Registry
clinicaltrials.gov
Start Date
October 4, 2023
End Date
December 15, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Indústria Brasileira Equipamentos Médicos - IBRAMED
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The participant (healthy volunteer) who has read and signed the informed consent form for the study.
  • Male or female ≥ 22 years and ≤ 65 years of age.
  • Subjects with a body mass index (BMI) of 30 or less and who have a greater volume of adipose tissue in the abdomen (except precordial region) and flanks.
  • Subject has not changed in weight more than 5% of body weight in the previous month.
  • Subject agrees to maintain his/her weight (i.e., within 5%) by not making major changes in his/her diet or exercise routine during the study.
  • Subject agrees to have photographs taken of the treatment area(s) during the scheduled periods.

Exclusion Criteria

  • Diabetes mellitus or need to administer or known history of subcutaneous injections in the area of intended treatment (e.g. heparin, insulin) in the last month;
  • Metabolic and/or liver diseases that compromise vitamin metabolism;
  • Being pregnant or planning to become pregnant during the study period (within the next 8 months);
  • Being breast-feeding or having breast-fed in the last 6 months;
  • Having a known sensitivity to cold, such as cold urticaria, Raynaud\'s disease, chilblains (pernio) or any known condition with a response to cold exposure that limits blood flow to the skin;
  • Irritated skin or presence of dermatitis;
  • Keloids or propensity for keloids in the area to be treated;
  • Having a history of hernia in the area(s) to be treated.
  • Any dermatological conditions, such as moderate to excessive skin laxity, or scarring at the location of the treatment sites that may interfere with treatment or evaluation (stretch marks are not an exclusion);
  • Have a history of a bleeding disorder or are taking any medications that, in the opinion of the investigator, may increase the risk of bruising;

Outcomes

Primary Outcomes

% reduction in fat layer assessed by ultrasound, adipometer and photography

Time Frame: Immediately after the procedure and 6 and 20 weeks after

Adipometer: to measure the thickest point within the treatment area. For the evaluation in the abdominal region, reference points located 5 cm to the side of the umbilical scar, both on the right and left sides, will be recorded. For the evaluation in the flank region, the measurement will be standardized using the axillary midline, being performed exactly in the central fold of each flank; Ultrasound: subcutaneous tissue between the anatomical planes. The probe will be positioned at the points previously marked in the treatment area, following the same measurement performed for adipometry; Photography: at fixed angles and postures with standardized disposable underwear. Three-dimensional images will be taken of the subjects in sagittal (left and right sides) and coronal (front and back sides) views at baseline and at the stipulated follow-up periods. The abdominal region will be exposed and the subject will be instructed to remain still while the camera captures an image.

Ocurrence of adverse events after de procedure assessed by clinical evaluation

Time Frame: After de procedure and 6 and 20 weeks after

Adverse events such as erythema, pain, edema or any other event that occurs in correlation with the treatment, through monitoring in the reassessments stipulated in the study and also in a questionnaire answered by the patient

Secondary Outcomes

  • Patient"s satisfaction assessed by GAIS scale(6 weeks and 20 weeks after the cryolipolysis procedure)

Study Sites (3)

Loading locations...

Similar Trials